Core Viewpoint - Via Biotechnology (01873) experienced a significant stock increase of over 18%, closing at 2.35 HKD with a trading volume of 64.71 million HKD, following the successful hosting of the Viva Biotech Innovation Forum 2026 during the J.P. Morgan Healthcare Conference, which focused on advancements in artificial intelligence and new drug types [1] Company Summary - The company showcased its capabilities in AI-enabled peptide drug development and the CRDMO platform during the forum, highlighting the acceleration of AI applications in key research and industrialization processes [1] - Analysts from Zheshang Securities (601878) expressed optimism regarding the company's sustained high profitability trend, driven by the increasing proportion of AI application projects in the CRO sector and the rollout of significant commercial projects in the CDMO space [1] - Guosheng Securities (002670) noted that the company's synergistic development of CRO and CDMO, along with AI-driven efficiency improvements and investment incubation ecosystem construction, positions it to benefit from the rising global innovation drug industry, leading to steady performance growth and long-term value release [1]
维亚生物尾盘涨超18% AI驱动研发提效及投资孵化生态构建